Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
11-29-13
New Malaria Target Identified With Potential to Prevent, Block and Treat Multiple Stages of the Malaria Life Cycle
Novartis scientists have discovered a new drug target for treating malaria. The discovery, which is published online in the journal Nature,2 identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental antimalarial compound clas...
POSTED
11-29-13
Neues Malaria-Target mit dem Potenzial zur Prophylaxe, Hemmung und Behandlung verschiedener Stadien des Malarialebenszyklus identifiziert
Wissenschaftler von Novartis haben ein neues Wirkstoff-Target zur Behandlung von Malaria gefunden. Ihrer Entdeckung zufolge, die in Nature online publiziert wurde,2 fungiert die Phosphatidylinositol-4-Kinase (PfPI4K) als Target für Imidazopyrazine, eine neuartige, experimentel...
POSTED
11-29-13
Identification d'une nouvelle cible du paludisme ayant le potentiel de prévenir, bloquer et traiter plusieurs stades du cycle de vie du paludisme
Les chercheurs de Novartis ont découvert une nouvelle cible médicamenteuse pour le traitement du paludisme. La découverte, publiée en ligne dans la revue Nature,2 identifie phosphatidylinositol-4-kinase (PfPI4K) comme cible des imidazopyrazines, une nouvelle classe de molécule...
POSTED
11-15-13
Novartis Honored with Outstanding Corporation Award by World Forum for Ethics in Business
The World Forum for Ethics in Business (WFEB) awarded Novartis the Ethics in Business Award in the Outstanding Corporation category. The WFEB is the public interest foundation focused on promoting and defending ethical approaches to business and corporate governance.
“This award recognizes...
POSTED
11-14-13
Novartis Honored by Malaria No More Corporate Citizenship Award in Recognition of Long-standing Commitment to Eliminating the Disease
In recognition of Novartis’ significant on-going contributions to malaria control and elimination, the company has been honored with the Global Corporate Citizenship Award at the Malaria No More International Honors annual benefit.
Since 2001 Novartis has delivered more than 600 million an...
POSTED
08-08-13
Novartis First Company Accredited with Global "CEO Cancer Gold Standard" for Outstanding Efforts in Cancer Prevention and Treatment
Novartis is the first company to earn global CEO Cancer Gold Standard accreditation by the non-profit organization CEO Roundtable on Cancer, a group of cancer fighting CEOs from a variety of industries, including healthcare. The designation recognizes the company’s efforts to pr...
POSTED
05-17-13
Novartis Wins GBCHealth Business Action on Health Award For Social Ventures Initiative
- GBCHealth recognizes Novartis Arogya Parivar (“Healthy Family”) initiative as one of the best corporate programs to address global health needs
- Arogya Parivar has improved access to medicine for 42 million patients across 33,000 villages in India
POSTED
04-26-13
Novartis Sponsored Restoration of Cultural Heritage Landmark in Spain Awarded Laureate in Coveted EU Europa Nostra Award
Novartis announced today that its Abadia Retuerta Abbey property, which has been under restoration since 2006, was recognized as one of the 15 best building conservation projects by the prestigious European Union Prize for Cultural Heritage/Europa Nostra. Architect Marco Serra led the project whi...
POSTED
04-25-13
Novartis Signs on to Support Malaria No More's Power of One Campaign to Stride Towards a Future Without Malaria
Novartis and Malaria No More, a leading global charity determined to end malaria deaths, announced today that they are joining forces on the Power of One campaign to help close the treatment gap and accelerate progress in the fight against malaria. Over the next three years, Novartis will support...
POSTED
04-25-13
More Than 16,500 Novartis Associates Worldwide Engage in Voluntary Activities For Community Partnership Day
Today more than 16,500 Novartis associates in 56 countries are engaging in voluntary activities to help their local communities in celebration of the company’s 17th Community Partnership Day (CPD). This annual event commemorates the 1996 creation of Novartis as a global leader in healt...
